B&K CORP-B (02396) Achieves First Patient Enrollment in Phase IIIa Trial for Pro-101-1 in Deep Second-Degree Burn Treatment

Stock News05-12

B&K CORP-B (02396) has announced that the Phase IIIa clinical trial for Pro-101-1, a product developed by the company for the treatment of deep second-degree burns, has recently completed enrollment of its first patient. Pro-101-1 is one of the company's core products. This clinical trial is a randomized, double-blind, placebo-controlled study designed to further evaluate the efficacy and safety of recombinant human platelet-derived growth factor (rhPDGF-BB) gel in treating deep second-degree burn wounds. The trial will also provide key parameters for the design of the subsequent Phase IIIb clinical trial, involving a large number of enrolled subjects. The completion of the first patient enrollment for the Pro-101-1 Phase IIIa trial represents another significant research and development advancement for the company in the field of burn and scald treatment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167182587?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167182587","market":"sg","top_or_hot":-1,"title":"B&K CORP-B (02396) Achieves First Patient Enrollment in Phase IIIa Trial for Pro-101-1 in Deep Second-Degree Burn Treatment","media":"Stock News","content":"<p>B&K CORP-B (02396) has announced that the Phase IIIa clinical trial for Pro-101-1, a product developed by the company for the treatment of deep second-degree burns, has recently completed enrollment of its first patient. Pro-101-1 is one of the company's core products. This clinical trial is a randomized, double-blind, placebo-controlled study designed to further evaluate the efficacy and safety of recombinant human platelet-derived growth factor (rhPDGF-BB) gel in treating deep second-degree burn wounds. The trial will also provide key parameters for the design of the subsequent Phase IIIb clinical trial, involving a large number of enrolled subjects. The completion of the first patient enrollment for the Pro-101-1 Phase IIIa trial represents another significant research and development advancement for the company in the field of burn and scald treatment.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>B&K CORP-B (02396) Achieves First Patient Enrollment in Phase IIIa Trial for Pro-101-1 in Deep Second-Degree Burn Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nB&K CORP-B (02396) Achieves First Patient Enrollment in Phase IIIa Trial for Pro-101-1 in Deep Second-Degree Burn Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-12 21:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>B&K CORP-B (02396) has announced that the Phase IIIa clinical trial for Pro-101-1, a product developed by the company for the treatment of deep second-degree burns, has recently completed enrollment of its first patient. Pro-101-1 is one of the company's core products. This clinical trial is a randomized, double-blind, placebo-controlled study designed to further evaluate the efficacy and safety of recombinant human platelet-derived growth factor (rhPDGF-BB) gel in treating deep second-degree burn wounds. The trial will also provide key parameters for the design of the subsequent Phase IIIb clinical trial, involving a large number of enrolled subjects. The completion of the first patient enrollment for the Pro-101-1 Phase IIIa trial represents another significant research and development advancement for the company in the field of burn and scald treatment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02396","symbol_name":"华芢生物-B","start_time":0,"source_url":"","article_id":"1167182587","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167182587","pubTimestamp":1778592020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"B&K CORP-B (02396) has announced that the Phase IIIa clinical trial for Pro-101-1, a product developed by the company for the treatment of deep second-degree burns, has recently completed enrollment...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02396":"华芢生物-B","BK1161":"生物科技"},"translate_title":"B&K CORP-B(02396)Pro-101-1深二度烧伤治疗IIIa期试验实现首例患者入组","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02396":1},"content_text":"B&K CORP-B (02396) has announced that the Phase IIIa clinical trial for Pro-101-1, a product developed by the company for the treatment of deep second-degree burns, has recently completed enrollment of its first patient. Pro-101-1 is one of the company's core products. This clinical trial is a randomized, double-blind, placebo-controlled study designed to further evaluate the efficacy and safety of recombinant human platelet-derived growth factor (rhPDGF-BB) gel in treating deep second-degree burn wounds. The trial will also provide key parameters for the design of the subsequent Phase IIIb clinical trial, involving a large number of enrolled subjects. The completion of the first patient enrollment for the Pro-101-1 Phase IIIa trial represents another significant research and development advancement for the company in the field of burn and scald treatment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167182587","isCrawlerRequest":true}